Latest News - Akorn Pharmaceuticals

Friday, February 02, 2018 | Glaucoma, Akorn Pharmaceuticals

Notification of Availability of Preservative-Free Cosopt PF

Days after being placed on the FDA shortage list, Akorn, the maker of glaucoma drug Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution), noted that Cosopt PF 2%/0.5% is "widely…

Read the full story

Monday, July 31, 2017 | Partnerships, Akorn Pharmaceuticals, AMD

Aerie Pharmaceuticals Enters into Collaboration with DSM Focused on Technology to Potentially Deliver Aerie Compounds to Treat Retinal Diseases

Aerie Pharmaceuticals announced that it has entered into a collaborative research, development, and license agreement with DSM. The research collaboration agreement includes an option to license DSM&r…

Read the full story

Friday, April 07, 2017 | Acquisitions/Mergers, Akorn Pharmaceuticals

Fresenius Considers Bid for Generic Drugmaker Akorn

Fresenius SE, Europe’s biggest publicly traded health-care provider, is weighing a bid for US generic drugmaker Akorn Inc., according to Bloomberg News, citing people familiar with the matter sa…

Read the full story

Wednesday, August 05, 2015 | Corporate Lawsuits, Akorn Pharmaceuticals, Allergan

Akorn Inc's Hi-Tech Pharmacal Infringes Allergan Glaucoma Drug Patents

An Akorn Inc unit's proposed generic glaucoma drug infringed three Allergan Inc patents on its Lumigan topical treatment for the eye disease, a U.S. appeals court ruled on Tuesday. The U.S. Court …

Read the full story

Friday, March 20, 2015 | FDA Approval/Clearance, Akorn Pharmaceuticals

Akorn Launches Phenylephrine HCl Ophthalmic Solution

Akorn announced that it has launched Phenylephrine HCl Ophthalmic Solution, USP, 2.5% and 10%. The launch follows an approval of a new drug application (NDA) for the product from the FDA on January 15…

Read the full story

Friday, January 16, 2015 | Akorn Pharmaceuticals

Akorn Confirms Generic Durezol Patent Challenge

Akorn confirmed that it has filed an abbreviated new drug application (ANDA) with the FDA seeking approval to market difluprednate ophthalmic emulsion 0.05%, according to a company news release. If ap…

Read the full story